Literature DB >> 22432611

Silencing or stimulation? siRNA delivery and the immune system.

Kathryn A Whitehead1, James E Dahlman, Robert S Langer, Daniel G Anderson.   

Abstract

Since its inception more than a decade ago, the field of short interfering RNA (siRNA) therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The power behind RNA interference (RNAi) therapy lies in its ability to specifically silence target genes of interest. As more biological data have become available, it has become evident that, in addition to mediating RNAi, siRNA molecules have the potential to potently induce the innate immune system. One of the significant challenges facing the field today is the differentiation between therapeutic effects caused by target-specific, RNAi-mediated gene silencing and those caused by nonspecific stimulation of the innate immune system. Unless appropriate experimental measures are taken to control for RNA-induced immunostimulation, genetic manipulation can be confused with immune activation. This review attempts to provide an accessible background in siRNA-relevant immunology and to highlight the ways in which siRNA can be engineered to avoid or provoke an innate immune response.

Mesh:

Substances:

Year:  2011        PMID: 22432611     DOI: 10.1146/annurev-chembioeng-061010-114133

Source DB:  PubMed          Journal:  Annu Rev Chem Biomol Eng        ISSN: 1947-5438            Impact factor:   11.059


  62 in total

Review 1.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 2.  Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics.

Authors:  Anuradha Kalani; Alka Tyagi; Neetu Tyagi
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 3.  Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases.

Authors:  Rutao Liu; Jing Liu; Xiaofei Ji; Yang Liu
Journal:  Metab Brain Dis       Date:  2013-12       Impact factor: 3.584

Review 4.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 5.  Delivery materials for siRNA therapeutics.

Authors:  Rosemary Kanasty; Joseph Robert Dorkin; Arturo Vegas; Daniel Anderson
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

6.  Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics.

Authors:  James E Dahlman; Kevin J Kauffman; Yiping Xing; Taylor E Shaw; Faryal F Mir; Chloe C Dlott; Robert Langer; Daniel G Anderson; Eric T Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

7.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Authors:  James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson
Journal:  Nat Nanotechnol       Date:  2014-05-11       Impact factor: 39.213

8.  Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells.

Authors:  Yunfeng Yan; Li Liu; Hu Xiong; Jason B Miller; Kejin Zhou; Petra Kos; Kenneth E Huffman; Sussana Elkassih; John W Norman; Ryan Carstens; James Kim; John D Minna; Daniel J Siegwart
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

9.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

10.  The autoinhibitory CARD2-Hel2i Interface of RIG-I governs RNA selection.

Authors:  Anand Ramanathan; Swapnil C Devarkar; Fuguo Jiang; Matthew T Miller; Abdul G Khan; Joseph Marcotrigiano; Smita S Patel
Journal:  Nucleic Acids Res       Date:  2015-11-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.